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Actinobacillus pleuropneumoniae is a major cause of pleuropneumo-
nia, an acute or chronic lung disease of pigs that causes signiﬁ-
cant morbidity, mortality and economic losses in the worldwide
pig industry (Bossé and others 2002, Gottschalk 2012). There are
15 established serovars of the bacterium determined by the com-
position of the capsular polysaccharide (Gottschalk 2012) with
another proposed based on serology alone (Sárközi and others
2015). Determining the serovar allows insights into the epidemi-
ology of A. pleuropneumoniae, for example, to map outbreaks of
disease, to identify introductions of serovars not previously
detected in countries and to assist in the formulation of bacterin
vaccines. Serovar prevalence varies from country to country and
with time (Dubreuil and others 2000, Gottschalk 2015). For
example, currently serovars 5 and 7 dominate in Canada
(Gottschalk and Lacouture 2015), whereas until the 1990s, it
was serovar 1 (Gottschalk 2015). In Australia, serovar 15 is
highly prevalent (Turni and others 2014) but is rarely reported
elsewhere, although it has been recently found in Canada
(Gottschalk and Lacouture 2014) and possibly also in Japan
(Koyama and others 2007).
The last prevalence study in the UK analysed A. pleuropneumo-
niae clinical isolates collected in England and Wales between the
years 1995 and 2007, with serovar 8 predominant (O’Neill and
others 2010). In that study, serovar was assigned on the basis of
PCR ampliﬁcation of chromosomal capsule-speciﬁc regions;
immunological serotyping by slide agglutination having been
shown erroneously to overestimate serovars 3 and 6 and underesti-
mate serovar 8 prevalence. Similar underestimation and overesti-
mation were also found in a study of Canadian isolates (Gottschalk
2015). In this study, the authors sought to determine whether the
serotype prevalence of A. pleuropneumoniae in England and Wales
had changed since 2007 and, in particular, whether new serovars,
such as 15, were now present. The isolates evaluated were obtained
from clinical cases of diseases in pigs due to A. pleuropneumoniae sub-
mitted to the Animal Health and Veterinary Laboratories Agency—
Weybridge (AHVLA), now the Animal and Plant Health Agency
(APHA), or Royal Veterinary College Diagnostic Laboratories.
Isolates were collected between 2008 and 2014. For each year, the
number of isolates (in brackets) is as follows: 2008 (N=14); 2009
(N=17); 2010 (N=8); 2011 (N=10); 2012 (N=30); 2013 (N=19)
and 2014 (N=15). Bacteria were grown on plates comprising Brain
Heart Infusion Agar supplemented with 10 mg/ml nicotinamide
adenine dinucleotide. Initially, serotyping was assessed by a multi-
plex PCR that can distinguish between serovars 1–3, 5–8, 10 and 12
(Bossé and others 2014). The PCR was based on the authors’ ori-
ginal serovar 3–6–8 PCR (Zhou and others 2008) but extended to
cover all of the serovars reported in England and Wales in the
authors’ 2010 study (O’Neill and others 2010) and those reported
to be prevalent in Europe and North America (Dubreuil and others
2000). A serovar 15-speciﬁc PCR (Turni and others 2014) was subse-
quently used on strains that were untypable by the 1–3, 5–8, 10 and
12 multiplex PCR. Genomic DNA puriﬁed using the QIAamp DNA
Mini Kit (Qiagen) or single colonies were used as the source of
DNA template for PCR reactions as previously described (Bossé and
others 2014). In addition to serovar-speciﬁc amplicons, the multi-
plex PCR ampliﬁes a region of the A. pleuropneumoniae-speciﬁc
apxIVA gene (Schaller and others 2001, Bossé and others 2014). All
isolates investigated in this study produced an apxIVA amplicon
conﬁrming that they were A. pleuropneumoniae. Comparison of the
seroprevalence of A. pleuropneumoniae in England and Wales in this
and the authors’ previous study is shown in Table 1.
As in the authors’ 2010 study, serovar 8 was the most pre-
dominant in years 2008–2014 in England and Wales, with a com-
paratively smaller percentage of serovars 2, 6, 7 and 12. The
England and Wales serovar proﬁle contrasts with that found in
other European countries. For example, serovar 9/11 predomi-
nates in the Czech Republic (Kucerova and others 2005) and
serovar 2 in Denmark (Klausen and others 2007), Norway and
Sweden (Gottschalk 2012). No serovar 3 isolates were found,
possibly reﬂecting the known low virulence of this serotype
(Rosendal and others 1985), and that the A. pleuropneumoniae
isolates evaluated were from clinically conﬁrmed cases. Four
TABLE 1: Percentage serovar distribution ofA. pleuropneumoniae
isolates in England and Wales-based studies
Percentage of isolates (number of isolates) in range of years indicated
Serovar 1995–2007* 2008–2014†
2 3.4 (13) 6.2 (7)
3 0.5 (2) –
6 10.1 (38) 7.1 (8)
7 5.3 (20) 8.0 (9)
8 78.0 (295) 71.7 (81)
12 2.7 (10) 3.5 (4)
NT – 3.5 (4)
*O’Neill and others (2010)
†Present study
NT, non-typable
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isolates were non-typable (NT) and subsequent PCR testing
established that these were not serovar 15 (Turni and others
2014). Due to their low numbers, the NT isolates were not
tested further. The NT isolates could be serovars 4, 9/11, 13, 14,
the newly described serovar 16 or variants such that the primers
used did not anneal to genomic DNA. Among these, only
serovar 9 has been previously reported in Great Britain
(McDowell and Ball 1994) or Scotland (Anon 2013).
In summary, the authors’ results suggest that serovar 8
A. pleuropneumoniae remains the predominant serovar causing
clinical disease outbreaks in England and Wales, as in the
authors’ previous study. Any vaccine to be used in the UK to
prevent disease caused by A. pleuropneumoniae should have a
component targeting serovar 8 isolates and, for near-maximal
coverage, additionally serovars 2, 6, 7 and 12.
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